Rituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus

Abdul Halim Abdul Gafor, Z. Soehardy, Mohd Shahrir Mohamed Said, Rozita Mohd, C. Y. Loo, S. Rashidi, C. T. Norella Kong

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is a typical autoimmune disease with manifestations due to unopposed production of autoantibodies against the patient's own cells. The clinical features are diverse, ranging from musculoskeletal involvement, lupus nephritis to cerebral and even haematological involvement. We report a case of a young woman with known SLE who developed thrombotic thrombocytopenic purpura (TTP) secondary to SLE resistant to conventional treatment with plasma exchange. She was then treated with rituximab (MabThera®), a CD20 monoclonal antibody, and showed remarkable improvement. To our best knowledge this is the first case reporting the use of rituximab in acute resistant TTP secondary to SLE.

Original languageEnglish
Pages (from-to)69-72
Number of pages4
JournalInternational Journal of Rheumatic Diseases
Volume11
Issue number1
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Thrombotic Thrombocytopenic Purpura
Systemic Lupus Erythematosus
Lupus Nephritis
Plasma Exchange
Autoantibodies
Autoimmune Diseases
Monoclonal Antibodies
Rituximab
Therapeutics

Keywords

  • Plasma exchange
  • Rituximab
  • Steroids
  • Systemic lupus erythematosus
  • Thrombotic thrombocytopenic purpura

ASJC Scopus subject areas

  • Rheumatology

Cite this

Rituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus. / Abdul Gafor, Abdul Halim; Soehardy, Z.; Mohamed Said, Mohd Shahrir; Mohd, Rozita; Loo, C. Y.; Rashidi, S.; Norella Kong, C. T.

In: International Journal of Rheumatic Diseases, Vol. 11, No. 1, 04.2008, p. 69-72.

Research output: Contribution to journalArticle

@article{190b61277223400b92f797ec37dbb5a7,
title = "Rituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus",
abstract = "Systemic lupus erythematosus (SLE) is a typical autoimmune disease with manifestations due to unopposed production of autoantibodies against the patient's own cells. The clinical features are diverse, ranging from musculoskeletal involvement, lupus nephritis to cerebral and even haematological involvement. We report a case of a young woman with known SLE who developed thrombotic thrombocytopenic purpura (TTP) secondary to SLE resistant to conventional treatment with plasma exchange. She was then treated with rituximab (MabThera{\circledR}), a CD20 monoclonal antibody, and showed remarkable improvement. To our best knowledge this is the first case reporting the use of rituximab in acute resistant TTP secondary to SLE.",
keywords = "Plasma exchange, Rituximab, Steroids, Systemic lupus erythematosus, Thrombotic thrombocytopenic purpura",
author = "{Abdul Gafor}, {Abdul Halim} and Z. Soehardy and {Mohamed Said}, {Mohd Shahrir} and Rozita Mohd and Loo, {C. Y.} and S. Rashidi and {Norella Kong}, {C. T.}",
year = "2008",
month = "4",
doi = "10.1111/j.1756-185X.2008.00334.x",
language = "English",
volume = "11",
pages = "69--72",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Rituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus

AU - Abdul Gafor, Abdul Halim

AU - Soehardy, Z.

AU - Mohamed Said, Mohd Shahrir

AU - Mohd, Rozita

AU - Loo, C. Y.

AU - Rashidi, S.

AU - Norella Kong, C. T.

PY - 2008/4

Y1 - 2008/4

N2 - Systemic lupus erythematosus (SLE) is a typical autoimmune disease with manifestations due to unopposed production of autoantibodies against the patient's own cells. The clinical features are diverse, ranging from musculoskeletal involvement, lupus nephritis to cerebral and even haematological involvement. We report a case of a young woman with known SLE who developed thrombotic thrombocytopenic purpura (TTP) secondary to SLE resistant to conventional treatment with plasma exchange. She was then treated with rituximab (MabThera®), a CD20 monoclonal antibody, and showed remarkable improvement. To our best knowledge this is the first case reporting the use of rituximab in acute resistant TTP secondary to SLE.

AB - Systemic lupus erythematosus (SLE) is a typical autoimmune disease with manifestations due to unopposed production of autoantibodies against the patient's own cells. The clinical features are diverse, ranging from musculoskeletal involvement, lupus nephritis to cerebral and even haematological involvement. We report a case of a young woman with known SLE who developed thrombotic thrombocytopenic purpura (TTP) secondary to SLE resistant to conventional treatment with plasma exchange. She was then treated with rituximab (MabThera®), a CD20 monoclonal antibody, and showed remarkable improvement. To our best knowledge this is the first case reporting the use of rituximab in acute resistant TTP secondary to SLE.

KW - Plasma exchange

KW - Rituximab

KW - Steroids

KW - Systemic lupus erythematosus

KW - Thrombotic thrombocytopenic purpura

UR - http://www.scopus.com/inward/record.url?scp=54949143273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949143273&partnerID=8YFLogxK

U2 - 10.1111/j.1756-185X.2008.00334.x

DO - 10.1111/j.1756-185X.2008.00334.x

M3 - Article

AN - SCOPUS:54949143273

VL - 11

SP - 69

EP - 72

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

IS - 1

ER -